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Introduction
Infection is a major cause of morbidity and one of 
the major causes of death after hematopoietic cell 
transplantation (HCT). Since infection may compromise 
the benefit of transplantation, each infectious 
complication remains a clinical challenge in patients 
after transplantation. In European Group for Blood and 
Marrow Transplantation (EBMT) analysis of 114,491 
patients with 5-year follow-up, a total of 55,668 patients 
were reported dead [1]. In 22.3% of all deaths, the 
cause was infection. The rate of deaths from infections 
varied over calendar time and posttransplant phase. 
Overall the rate of infectious deaths decreased in all 
phases after autologous HCT (auto-HCT), and up to 
day 100 and beyond after allogeneic HCT (allo-HCT) 
which was the second cause of death after auto-HCT 
and third after allo-HCT.
With respect to the risk of infectious complications, 
posttransplant period is usually divided into the 
following intervals: very early (up to day 30 and 
beyond), early (between days 30 and 100), late 
(between day 100 and 1 year), and very late (beyond 
1 year). Alternatively, the phases can be divided 
into pretransplant phase, neutropenic phase, and 
immunosuppression phase; in allo-HCT setting, 
additional phase of immunosuppressive prophylaxis 
and graft-versus-host disease (GVHD) is distinguished. 
The risk of infections is particularly high during very 
early phase due to the toxicity of conditioning and 
neutropenia, as well as immunosuppressive therapy 
in case of allo-HCT; additionally, immunosuppression 
can be continued for many months after hematological 
recovery, especially in patients diagnosed with GVHD. 
Incidence of infections is particularly high during very 
early and early posttransplant phase [2-6]; however, 
the patient remains at risk of infectious complications 
from the beginning of conditioning regimen through 
the entire posttransplant period.
All Polish hematopoietic cell transplant centers were 
invited to participate in the survey on proposed 
prophylactic pharmacological approach for patients 
undergoing auto- or allo-HCT, both in pediatric and 
adult settings. This report presents the results of the 
survey.
Methods
During Transplant Workshop of Polish Federation of 
Bone Marrow Transplant Centers in Poznan, dated 
October 12, 2019, a survey on proposed antimicrobial 
prophylaxis was distributed, and one questionnaire per 
center was prepared. Based on their own experience, 
the centers were asked to suggest antibacterial, 
antifungal, and antiviral prophylaxis in auto- and allo-
HCT settings, with respect to the pretransplant phase, 
neutropenic phase, immunosuppressive prophylaxis 
phase and in case of GVHD. Additional questions 
were related to other supportive therapies and key 
diagnostic tests. Both pediatric and adult centers 
answered the same questionnaire. Vaccinations were 
not included in the survey.
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Five adult and one pediatric centers perform auto-HCT only; however, 
they partially answered the allo-HCT section, as the survey questions 
were about the recommended approach.
No Bioethical Committee agreement was necessary for this study, as 
no patients were involved. All participants of the survey are coauthors 
of this manuscript and they gave their agreement for publication.
Results and Discussion
A total number of 23 centers participated, including 6 for pediatric 
and 17 for adult patients. The summary of prophylaxis proposed by 
the centers with respect to auto- and allo-HCT and with respect to 
pre- and posttransplant phases in allo-HCT setting is shown in table I.
Prophylaxis in auto- and allo-HCT settings
Antibacterial prophylaxis
More than half of adult centers both in auto- and allo-HCT patients prefer 
to use quinolones (ciprofloxacin or levofloxacin). Some of the adult 
centers are in favor of use of oral penicillins (amoxicillin ± clavulanate 
or V-cyllin) mainly in allo-HCT setting. The choice of prophylaxis in 
pediatric centers is split between ciprofloxacin and amoxicillin, both 
in allo- and auto-HCT settings. Additionally, half of the centers are 
willing to use V-cyllin after allo-HCT. The prophylactic use of other 
antibacterial compounds is rare both in pediatric and adult centers.
Antifungal prophylaxis
All pediatric and adult centers use fluconazole in patients after auto-
HCT, and selection of antifungals in allo-HCT patients is variable and 
it includes posaconazole, voriconazole, fluconazole, and micafungin, 
with the exception of general avoidance of prophylactic use of 
voriconazole in pediatric centers. One adult center uses caspofungin 
during conditioning before allo-HCT with antithymocyte globulin 
(ATG). More than half adult centers perform regular weekly testing 
for galactomannan (GM) in all allo- and auto-HCT patients. It is also 
the rule for allo-HCT, but not for auto-HCT pediatric patients.
Antiviral prophylaxis
All adult centers use acyclovir in allo- and auto-HCT settings, and 
all pediatric centers use acyclovir in allo-HCT patients while only 
exceptionally in auto-HCT setting. One adult center uses ganciclovir 
during conditioning before allo-HCT with ATG. Almost all adult and 
pediatric centers perform regular weekly testing for Cytomegalovirus 
(CMV)  DNA and Epstein-Barr virus (EBV) DNA in allo-HCT patients. 
Some adult centers emphasize the necessity of use of letermovir in 
CMV-seropositive recipients.
Other antimicrobial prophylaxis
Almost all centers use cotrimoxazole in prophylaxis against 
pneumocystodosis and toxoplasmosis. Almost all pediatric and a 
few adult centers perform regular intravenous immunoglobulin (IVIG) 
supplementation, mainly in allo-HCT patients.
Prophylaxis in various phases of allo-HCT
Antibacterial prophylaxis 
Antibacterial prophylaxis in allo-HCT setting is rarely used during 
conditioning period by the centers, while virtually all pediatric 
and adult centers use prophylaxis both during neutropenia and 
immunosuppressive treatment and/or GVHD phase.
Antifungal prophylaxis
Antifungal prophylaxis in allo-HCT setting is very rarely used by 
adult centers during conditioning period, while virtually all pediatric 
and adult centers use antifungal prophylaxis both during neutropenia 
and immunosuppressive treatment and/or GVHD phase. Additionally, 
more than half pediatric centers also use antifungal prophylaxis 
during conditioning. None of the centers use voriconazole during 
conditioning. Itraconazole tablets are used exceptionally in one 
center only.
Antiviral prophylaxis
Acyclovir is recommended for prophylaxis both before HCT and 
during neutropenia and immunosuppressive treatment by almost all 
centers.
Other antimicrobial prophylaxis
Cotrimoxazole in prophylaxis is used both during neutropenia and 
immunosuppressive therapy periods in almost all centers, and 
also in part of the centers before HCT. Supplementation of IVIG to 
maintain concentration 4 g/L is performed both during neutropenia 
and immunosuppressive therapy in almost all centers.
Clinical implications of the survey
The results of this survey underline the value of antimicrobial 
prophylaxis in patients undergoing HCT and good awareness of this 
issue in all transplant centers. Virtually all pediatric and adult centers 
use antibacterial, antifungal, antiviral, and anti-pneumocystodosis 
prophylaxis both in allo- and auto-HCT patients. There are some 
differences regarding specific drugs, especially with respect to the 
lower use of quinolones in pediatric patients. The most preferred 
combinations of drugs are: quinolones and penicillins, fluconazole 
and posaconazole, and acyclovir and cotrimoxazole. Posaconazole 
and voriconazole are used exclusively in allo-HCT patients in primary 
and secondary prophylaxis as a result of reimbursement program of 
these drugs in Poland. This is also in line with international guidelines 
of antimicrobial prophylaxis.
The results of this survey reflect pharmacological antimicrobial 
prophylaxis practices used in Polish transplant centers. They 
also reflect drug availability and reimbursement in Poland, since 
letermovir, a new anti-CMV compound, recommended for CMV-
seropositive allo-HCT recipients is not used in Poland.
This survey may be used to create universal national guidelines for 
Polish HCT centers which are compatible with international guidelines 
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Table I. Proposed anti-infective prophylaxis
Pediatric (n = 6) Adult (n = 17) Total (n = 23)
Auto Allo Auto Allo Auto Allo
Antibacterial 
Quinolones:  Ciprofloxacin 2 4 9 8 11 12
Levofloxacin - - 6 6 6 6
Penicillins: Amoxicillin ± Clavulanian 3 4 1 5 4 9
V-cyllin - 3 1 8 1 11
Cephalosporines: Cefuroxime 1 1 1 - 2 1
Aminoglycosides (oral) 1 1 - - 1 1
Macrolides: Azithromycin - 1 - - - 1
Rifaximin - - 1 1 1 1
Antifungal 
Posaconazole - 4 - 12 - 16
Voriconazole - 1 - 10 - 11
Fluconazole 6 5 17 10 23 15
Itraconazole - 1 1 1 1 2
Mycamine - 3 - 7 - 10
Galactomannan testing ≥ 1/week 1 4 8 12 9 16
Other: Mannan or BDG - - 2 2 2 2
Antiviral
Acyclovir 1 6 17 16 18 22
Other - - - - - -
CMV DNA ≥ 1/week - 6 - 14 - 20
EBV DNA ≥ 1/week - 6 - 12 - 18
Other antimicrobial prophylaxis
Cotrimoxazole 4 6 17 13 21 19
IVIG supplementation 3 5 - 6 3 11
Other: pentamidine 1 1 - - 1 1
Prophylaxis in allo-HCT patients with respect to transplant phase
Pediatric (n = 6) Adult (n = 17) Total (n = 23)
Pre HCT Neutropenia GVHD IST Pre HCT Neutropenia GVHD IST Pre HCT Neutropenia GVHD IST
Antibacterial 
Quinolones: Ciprofloxacin 2 4 4 1 8 6 3 12 10
Levofloxacin - - - 3 7 7 3 7 7
Penicillins: Amoxicillin ± Clavulanian 1 4 4 1 2 6 2 6 10
V-cyllin - 1 4 - 1 8 - 2 12
Cephalosporines: Cefuroxime - - - - 1 - - 2 -
Aminoglycosides (oral) 1 - - - - - 1 - -
Macrolides: Azithromycin - 1 1 - - - - 1 1
Rifaximin - - - - 1 - - 1 -
Antifungal 
Posaconazole 3 3 4 1 3 12 4 6 16
Voriconazole - 1 1 - 5 9 - 6 10
Fluconazole 4 5 4 4 15 6 8 20 10
Itraconazole - - 1 - - - - - 1
Mycamine 2 2 2 1 5 2 3 7 5
Galactomannan testing ≥ 1/week 1 4 4 3 10 8 4 14 12
Other: Mannan or BDG - - - - 2 1 - 2 1
Antiviral
Acyclovir 3 6 6 13 15 14 16 21 20
Other - - - - - - - - -
CMV DNA ≥ 1/week 4 6 6 2 7 11 6 13 17
EBV DNA ≥ 1/week 4 6 6 - 5 10 4 11 16
Other antimicrobial prophylaxis
Cotrimoxazole 4 5 6 7 11 11 11 16 17
IVIG supplementation 1 5 5 1 2 6 2 7 11
Other: pentamidine 1 1 1 - - - 1 1 1
BDG – beta-d-glucan; GVHD – graft-versus-host disease; IST – immunosuppressive therapy; IVIG – intravenous immunoglobulin
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[7-15]. It may also serve as a useful tool for any local or multicenter 
epidemiological analyses.
Authors’ contributions
JS, LG – involved in design of the study. JS, LG – wrote manuscript. 
JS, LG, AŁ, KC – performed survey. MU, AC, LG, KC – involved in 
critical review. All authors approved the final manuscript.
Conflict of interest




The work described in this article has been carried out in accordance 
with the Code of Ethics of the World Medical Association (Declaration 
of Helsinki) for experiments involving humans; EU Directive 2010/63/
EU for animal experiments; Uniform requirements for manuscripts 
submitted to biomedical journals.
[1] Styczynski J, Tridello G, Koster L, et al. Death after hematopoietic stem 
cell transplantation: changes over calendar year time, infections and 
associated factors. Bone Marrow Transplant 2020;55:126–36.
[2] Styczynski J, Czyzewski K, Wysocki M, et al. Increased risk of 
infections and infection-related mortality in children undergoing 
haematopoietic stem cell transplantation compared to conventional 
anticancer therapy: a multicentre nationwide study. Clin Microbiol 
Infect 2016;22:179.e1–e10.
[3] Czyzewski K, Styczynski J, Giebel S, et al. Age-dependent 
determinants of infectious complications profile in children and 
adults after hematopoietic cell transplantation: lesson from the 
nationwide study. Ann Hematol 2019;98(9):2197–211.
[4] Czyzewski K, Galazka P, Fraczkiewicz J, et al. Epidemiology and 
outcome of invasive fungal disease in children after hematopoietic 
cell transplantation or treated for malignancy: Impact of national 
programme of antifungal prophylaxis. Mycoses 2019;62:990–8.
[5] Styczynski J. Infectious complications in children and adults with 
hematological malignancies. Acta Haematol Pol 2019;50:167–73.
[6] Styczynski J. ABC of viral infections in hematology: focus on 
herpesviruses. Acta Haematol Pol 2019;50:159–66.
[7] Styczynski J, van der Velden W, Fox CP, et al. Management of Epstein-
Barr Virus infections and post-transplant lymphoproliferative 
disorders in patients after allogeneic hematopoietic stem cell 
transplantation: Sixth European Conference on Infections in 
Leukemia (ECIL-6) guidelines. Haematologica 2016;101:803–11.
[8] Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines 
for diagnosis and treatment of adenovirus infection in leukemia and 
stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis 
2012;14:555–63.
[9] Ljungman P, de la Camara R, Robin C, et al. Guidelines for the 
management of cytomegalovirus infection in patients with 
haematological malignancies and after stem cell transplantation 
from the 2017 European Conference on Infections in Leukaemia 
(ECIL 7). Lancet Infect Dis 2019;19:e260–72.
[10] Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P. 
European guidelines for prevention and management of influenza 
in hematopoietic stem cell transplantation and leukemia patients: 
summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, 
EORTC, ICHS, and ELN. Transpl Infect Dis 2013;15:219–32.
[11] Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for 
empirical antibacterial therapy for febrile neutropenic patients in the era 
of growing resistance: summary of the 2011 4th European Conference 
on Infections in Leukemia. Haematologica 2013;98:1826–35.
[12] Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on 
Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, 
and treatment of invasive fungal diseases in paediatric patients with 
cancer or allogeneic haemopoietic stem-cell transplantation. Lancet 
Oncol 2014;15:e327–40.
[13] Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment 
of invasive candidiasis, aspergillosis and mucormycosis in leukemia 
and hematopoietic stem cell transplant patients. Haematologica 
2017;102:433–44.
[14] Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for 
preventing Pneumocystis jirovecii pneumonia in patients with 
haematological malignancies and stem cell transplant recipients. 
J Antimicrob Chemother 2016;71:2397–404.
[15] Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for 
antifungal management in leukemia and hematopoietic stem cell 
transplant recipients: summary of the ECIL 3 – 2009 update. Bone 
Marrow Transplant 2011;46:709–18.
References
